Tenaya Therapeutics Inc TNYA Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Aug 29, 2023 (filed on Aug 29, 2023)

Insider Name:

Hoey Timothy

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-7,243

Price:

$4.26
Aug 16, 2023 (filed on Aug 18, 2023)

Insider Name:

Hoey Timothy

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-4,007

Price:

$3.81
Aug 16, 2023 (filed on Aug 18, 2023)

Insider Name:

Tingley Whittemore

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-5,563

Price:

$3.81
Aug 16, 2023 (filed on Aug 18, 2023)

Insider Name:

Patterson Leone D

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-4,452

Price:

$3.81
Aug 16, 2023 (filed on Aug 18, 2023)

Insider Name:

Ali Faraz

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-5,563

Price:

$3.81
Jun 09, 2023 (filed on Jun 12, 2023)

Insider Name:

Walsh Jeffrey T.

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

29,532

Price:

--
Jun 09, 2023 (filed on Jun 12, 2023)

Insider Name:

Williams R Sanders

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

29,532

Price:

--
Jun 09, 2023 (filed on Jun 12, 2023)

Insider Name:

Stehman-Breen Catherine

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

29,532

Price:

--
Jun 09, 2023 (filed on Jun 12, 2023)

Insider Name:

Srivastava Deepak

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

29,532

Price:

--
Jun 09, 2023 (filed on Jun 12, 2023)

Insider Name:

Parschauer Karah Herdman

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

29,532

Price:

--

Filings by filing date

Aug 29, 2023 (filed on Aug 29, 2023)

Insider Name:

Hoey Timothy

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-7,243

Price:

$4.26
Aug 16, 2023 (filed on Aug 18, 2023)

Insider Name:

Hoey Timothy

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-4,007

Price:

$3.81
Aug 16, 2023 (filed on Aug 18, 2023)

Insider Name:

Tingley Whittemore

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-5,563

Price:

$3.81
Aug 16, 2023 (filed on Aug 18, 2023)

Insider Name:

Patterson Leone D

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-4,452

Price:

$3.81
Aug 16, 2023 (filed on Aug 18, 2023)

Insider Name:

Ali Faraz

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-5,563

Price:

$3.81
Jun 09, 2023 (filed on Jun 12, 2023)

Insider Name:

Walsh Jeffrey T.

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

29,532

Price:

--
Jun 09, 2023 (filed on Jun 12, 2023)

Insider Name:

Williams R Sanders

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

29,532

Price:

--
Jun 09, 2023 (filed on Jun 12, 2023)

Insider Name:

Stehman-Breen Catherine

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

29,532

Price:

--
Jun 09, 2023 (filed on Jun 12, 2023)

Insider Name:

Srivastava Deepak

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

29,532

Price:

--
Jun 09, 2023 (filed on Jun 12, 2023)

Insider Name:

Parschauer Karah Herdman

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

29,532

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	171 Oyster Point Blvd., Suite 500 SOUTH SAN FRANCISCO CA 94080
Tel:	N/A
Website:	https://www.tenayatherapeutics.com
IR:	See website

Key People

Faraz Ali Chief Executive Officer, Director	Leone D. Patterson Chief Financial and Business Officer	Timothy Hoey Chief Scientific Officer
Whittemore Tingley Chief Medical Officer

Business Overview

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of disease-modifying therapies that includes both gene therapies and small molecules discovered internally and developed using its product platforms and core capabilities to target defined sub-populations of patients with rare or prevalent forms of heart disease. Its product platforms include Gene Therapy, Cellular Regeneration and Precision Medicine to discover novel therapies for various forms of heart disease. The Company's lead product candidates include, TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy, TN-301, a small molecule for heart failure with preserved ejection fraction, and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC).

Financial Overview

For the nine months ended 30 September 2023, Tenaya Therapeutics Inc revenues was not reported. Net loss increased 4% to $94.1M. Higher net loss reflects Research and development - Balancing v increase of 8% to $70M (expense), Stock-based Compensation in SGA increase of 37% to $6.2M (expense), Stock-based Compensation in R&D increase of 38% to $5.2M (expense).

Employees:	141 as of Dec 31, 2022

Reporting Currency:	U.S. Dollars
Enterprise value:	$8.34M as of Sep 30, 2023
Annual revenue (TTM):	$0.00M as of Sep 30, 2023
EBITDA (TTM):	-$125.65M as of Sep 30, 2023
Net annual income (TTM):	-$127.67M as of Sep 30, 2023
Free cash flow (TTM):	-$104.47M as of Sep 30, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	68,111,019 as of Nov 2, 2023
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization